Merck & Co., Inc. MRK
132.73 USD -5.05 (-3.67%)
As ofNov 19, 2026, 1:06 PM EST
132.53 Day range 139.17
94.97 52-week range 156.45
- YTD
- +26.10%
- 1 year
- +39.64%
News
benzinga.com AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples AstraZeneca commits $200 million to Tempus AI in a master services agreement renewal through 2031, while William Blair maintains a Market Perform rating.
benzinga.com Technology Only Sector Higher Thursday As Defensives Fall Thursday's regular session has one sector higher and 10 lower, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with Technology sitting…benzinga.com Halozyme Therapeutics Says Disappointed That Higher Regional Court Overturned The Preliminary Injunction Ordering Merck To Refrain From Distributing And Offering Keytruda In Germany Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme), today provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck to…
seekingalpha.com Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference Transcript Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference Transcript
marketbeat.com Merck & Co. Eyes Kidney Cancer Data as Vaccine Research Expands Beyond Melanoma Merck & Co., Inc. NYSE: MRK is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the…
benzinga.com Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial Immutep posts an 81.1% 12-month disease-free survival rate in its Phase 2 soft tissue sarcoma study and plans a new trial in 2027.
businesswire.com Merck and Isomorphic Labs Enter Strategic Research Collaboration RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a…
zacks.com Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy? MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.
zacks.com Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline? MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.
benzinga.com Growth Leads Sectors In Wednesday Trading As Cyclicals Trail Five sectors are trading higher and six are lower in Wednesday's regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single…
benzinga.com Merck Pulls Plug On Acquired Drug after Safety Review Merck discontinues its nemtabrutinib and BELLWAVE leukemia clinical program after an external review found risks may outweigh benefits.
businesswire.com Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director RAHWAY, N.J.--(BUSINESS WIRE)--Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director.
reuters.com Merck stops trials of blood cancer drug after risk assessment Merck stops trials of blood cancer drug after risk assessment
businesswire.com Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program…
benzinga.com Eli Lilly Short Interest Rises, Remains Below August Peak Eli Lilly and Co. (NYSE:LLY) short sellers added to their positions, with the latest report following the company’s Q3 2026 earnings release.Short interest rose 3.64% to 7.21 million shares as of the…
businesswire.com Merck Announces First-Quarter 2027 Dividend RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2027 Dividend.
247wallst.com Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead SCHD anchors countless retirement portfolios, yet its payout barely budged this past year while living costs kept climbing. Four household-name stocks promise faster raises, but each carries a risk…benzinga.com Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III…
defenseworld.net Merck & Co., Inc. (NYSE:MRK) Share Price Breaks Below Fifty Day Moving Average Following Insider Selling Merck and Co., Inc. (NYSE: MRK - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday following insider selling activity. The stock has a fifty day…
fool.com Is Merck's Stock Still a Good Buy at $150? Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line. It remains likely, however, that its revenue will drop off in the near future as key patents on…
247wallst.com How Much Does a 56-Year-Old Need Invested to Replace a $145,000 Salary With Dividends? Replacing a paycheck with dividends sounds simple until you see the price tag at different yields. Then a few overlooked details, from taxes to payroll deductions, quietly shrink the target, and one…
247wallst.com Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive One melanoma headline turned a $63 stock into a market darling, and Moderna's CEO just told Jim Cramer when patients could get the shot. Does the price already bake in the cancer breakthrough, or is…
benzinga.com Meet Wall Street’s New Dividend King: SCHD’s $27.5B Inflow Surge Signals Shift Away from AI Schwab U.S. Dividend Equity ETF (SCHD) is now America's largest dividend ETF, overtaking VIG. Is Wall Street changing its mind on AI?
seekingalpha.com Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November I expect Nike (NKE) to raise its dividend 1.2–2.4%, as weak sales, flat EPS and a payout ratio around 80% constrain growth. Matthews International (MATW) risks a dividend cut; Hormel (HRL) faces an…
defenseworld.net Merck & Co., Inc. $MRK Stock: Aberdeen Group plc Decreases Stake Aberdeen Group plc cut its holdings in Merck and Co., Inc. (NYSE: MRK) by 87.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.…
247wallst.com He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment A retiree on Original Medicare finishes melanoma surgery and hears about a personalized vaccine that could cut his odds of relapse. Whether he can get it, and who pays for what, hinges on a…
businesswire.com Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of…benzinga.com EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Merck’s WELIREG Plus Lenvatinib For Treatment Of Advanced Renal Cell Carcinoma With Clear Cell Component; Final Decision Expected In Next Two Months Opinion granted based on positive progression-free survival results from the Phase 3 LITESPARK-011 trialIf approved, this regimen will be the first and only approved combination of a HIF-2α inhibitor…
businesswire.com Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products…
benzinga.com FDA Reportedly Shelves Fast-Track Drug Review Pilot Program During Leadership Vacuum: Report The FDA reportedly shelves its fast-track drug voucher pilot amid internal chaos, returning review oversight to career scientists.
marketbeat.com 3 Pharmaceutical Stocks That Offer Safety and Growth Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI…
marketbeat.com What Merck KGaA (MRK) Said on Its Q3 Earnings Call Merck KGaA ETR: MRK raised its full-year 2026 outlook for the third time after faster third-quarter sales growth in its Life Science and Electronics businesses offset pressure on its Healthcare…
benzinga.com Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities Moderna raises its 2026 revenue forecast to 15%-25% and accelerates oncology investments, expanding its mRNA platform into new therapies.
businesswire.com Merck to Participate in the Jefferies Global Healthcare Conference in London RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference in London.
benzinga.com Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.
benzinga.com Cyclicals Lead Sectors In Wednesday Trading As Defensives Trail Five sectors are higher and six are lower in Wednesday's regular session, with cyclical sectors holding two of the top three positions. Technology sits well clear of the rest, separated from the next…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.benzinga.com 'Merck KGaA lands FDA nod for joint tumor drug it licensed from Abbisko'- Endpoints News https://endpoints.news/merck-kgaa-lands-fda-nod-for-joint-tumor-drug-it-licensed-from-abbisko/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
benzinga.com Merck Reports Phase 2b Results For Efinopegdutide In MASH, Meaningful Improvements Were Observed In Liver Fibrosis Without Worsening Of Steatohepatitis, A Key Secondary Histologic Endpoint; Results Presented At The Liver Meeting And Published In The Lancet Efinopegdutide demonstrated a statistically significant greater proportion of participants achieved MASH resolution without worsening of fibrosis versus placebo at 52 weeksMeaningful improvements…
benzinga.com 11 Of 11 Sectors Rise Monday As Growth Leads All 11 sectors are higher in Monday’s regular session, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing…
benzinga.com Moderna Stuns Wall Street With Surprise Profit, Raises Outlook Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
benzinga.com Growth Lead Sectors In Friday Trading As Defensives Trail Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…benzinga.com Merck Initiates Its ENHANCE-3 Phase 3 Randomized Clinical Trial Evaluating OHTUVAYRE For The Prevention Of Chronic Obstructive Pulmonary Disease Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care…
benzinga.com Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $155 Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $145 to $155.
benzinga.com Merck To Present New Data Across Its HIV Treatment And Prevention Pipeline And Portfolio At HIV Drug Therapy Glasgow 2026 Presentations include data on daily and investigational once-weekly oral treatments and investigational once-monthly oral HIV pre-exposure prophylaxisNew data include Phase 3 subgroup analyses and…
benzinga.com Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.benzinga.com JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $175 JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $165 to $175.
benzinga.com Merck One of Top Large-Cap Biopharma Picks-Analyst Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.benzinga.com RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $140 RBC Capital analyst Trung Huynh maintains Merck & Co (NYSE:MRK) with a Sector Perform and lowers the price target from $145 to $140.
benzinga.com Defensives Lead Sectors In Friday Trading As Growth Trails Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…
